Table 4.

Univariate Cox analysis on the effect of antivirals on the clinical outcome with either hepatitis B or hepatitis C

EtiologyPrimary Composite End PointProgression to ESKDOverall Mortality
Unadjusted Hazard Ratio (95% Confidence Interval) P ValueUnadjusted Hazard Ratio (95% Confidence Interval) P ValueUnadjusted Hazard Ratio (95% Confidence Interval) P Value
Usage of antivirals in hepatitis B0.49 (0.19 to 1.30)0.150.722 (0.17 to 3.16)0.670.60 (0.18 to 2.03)0.42
Usage for DAA in hepatitis C1.12 (0.53 to 2.38)0.760.83 (0.27 to 2.56)0.753.80 (0.90 to 16.1)0.07
  • DAA, direct-acting antivirals.